In another positive development, Pfizer won a bid in a London court to invalidate two of GSK Plc’s GSK patents relating to its respiratory syncytial virus (RSV) vaccine. Also Read: UK Chooses ...
Quebec is rolling out its fall vaccination campaign against respiratory viruses, as contagion levels of COVID-19 and other ...
In anticipation of the winter season an increased circulation of respiratory viruses is expected with a peak in the coming weeks – and the free fall vaccination campaign will begin soon. Quebec’s ...
Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.
A new COVID variant, XEC, is gaining traction in the U.S. and is estimated to account for up to 13% of cases. The strain is a recombinant of two JN.1 lineage viruses, with new COVID shots expected to ...
COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.
Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...